Welcome to our dedicated page for Bausch Health Companies news (Ticker: BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.
Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.
Salix Pharmaceuticals, part of Bausch Health Companies (BHC), announced it will present four research posters at the Society of Hospital Medicine (SHM) Converge 2022, held from April 7-10 in Nashville, TN. The featured studies cover XIFAXAN® (rifaximin) for hepatic encephalopathy and RELISTOR® (methylnaltrexone bromide) for opioid-induced constipation. Key findings include XIFAXAN’s effectiveness in reducing emergency department visits and RELISTOR’s safety profiles. These presentations aim to enhance awareness of treatment options in gastroenterology.
Summary not available.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced plans to reduce debt by $200 million by paying down senior secured term loans on March 31, 2022. This strategic move will be financed through cash generated from operations, demonstrating the company's commitment to improving its financial health. Bausch Health continues to focus on enhancing its portfolio in therapeutic areas such as eye health, gastroenterology, and dermatology.
Bausch Health and Clearside Biomedical announced the U.S. commercial launch of XIPERE®, the first FDA-approved therapy for suprachoroidal injection, designed to treat macular edema associated with uveitis. This therapy aims to address a serious condition affecting approximately 300,000 Americans, which can lead to vision loss. Key features include targeted delivery through the proprietary SCS Microinjector®, providing higher bioavailability and lower side effects compared to traditional methods. Training for eye care professionals on administration techniques is highlighted as crucial for successful implementation.
Bausch Health Companies (NYSE/TSX: BHC) announced a study demonstrating that FDA-approved medications for opioid-induced constipation (OIC), particularly RELISTOR®, significantly reduce hospitalization rates and costs. Research published in Advances in Therapy showed a 64% lower chance of hospitalization for OIC patients treated with OIC-Rx compared to those who were not. Furthermore, patients treated with RELISTOR had a reduction of $781 in healthcare costs per emergency department encounter. The study highlights the potential healthcare benefits and cost-effectiveness of using RELISTOR in OIC management.
Solta Medical Corporation, a subsidiary of Bausch Health Companies Inc. (BHC), has appointed Gary Gemignani as Chief Financial Officer, effective March 28, 2022. Gemignani brings over 35 years of experience in finance, previously serving as CFO for various pharmaceutical firms. His extensive background is expected to support Solta as it prepares for a potential IPO following a public filing on February 8, 2022. The IPO will involve Solta’s common shares, pending market conditions and regulatory approvals.
Bausch Health Companies Inc. (NYSE/TSX: BHC) announced new analyses for its dermatology products IDP-126 Gel, DUOBRII®, and SILIQ® at the AAD Annual Meeting from March 25-29, 2022. The investigational IDP-126 Gel aims to treat moderate-to-severe acne and could become a first-in-class therapy if approved. DUOBRII® effectiveness for maintaining skin clearance was also highlighted. Additionally, the company introduced a JUBLIA® virtual reality experience to educate about onychomycosis, impacting 35 million people in the U.S. annually.
Bausch Health Companies (NYSE/TSX: BHC) announced participation in two upcoming investor conferences. The events include the Cowen & Co. 42nd Annual Health Care Conference on March 8, 2022, at 12:50 p.m. ET, and the Barclays Global Healthcare Conference on March 15, 2022, at 11:15 a.m. ET. Key executives participating include Joseph C. Papa, Sam Eldessouky, and Arthur J. Shannon. Live webcasts will be available on the company's Investor Relations page.
Bausch Health Companies (NYSE/TSX: BHC) announces the opening of applications for the 2022 Aspire Higher Scholarship program, targeting students affected by dermatologic conditions. The program, active since 2013, will award nine scholarships of up to $10,000 each to aid educational pursuits. Applicants must submit recommendations and an essay detailing their experiences. This initiative has granted 60 scholarships totaling $828,000 over the years. Applications are open until May 31, 2022, with recipients announced in summer 2022.
On March 1, 2022, Salix Pharmaceuticals, part of Bausch Health (NYSE: BHC), partnered with the Colon Cancer Coalition to promote colorectal cancer screening awareness. The initiative, known as the Faces of Blue campaign, will share patient stories to encourage screenings, especially following the U.S. Preventive Services Task Force's guideline lowering the screening age to 45. This change affects approximately 45 million Americans now eligible for early detection screenings. Salix aims to enhance education and outreach through new resources and social media partnerships.